Evidence map›Paper›PMID 42043235›Full record

ArticleViruses2026

Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer.

Ashwin Ganti, Patrick W McGarrah, Harry Fuentes Bayne, Casey Fazer-Posorske, Binav Baral, Daniel J Ma, Scott C Lester, David M Routman, Michelle A Neben-Wittich, Jessica M Wilson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ashwin GantiDivision of Hematology-Oncology, University of California San Diego, San Diego, CA 92037, USA.ORCID 0000-0002-4576-2557
Patrick W McGarrahDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-0664-9447
Harry Fuentes BayneDivision of Hematology-Oncology, University of California San Diego, San Diego, CA 92037, USA.ORCID 0000-0002-7837-8359
Casey Fazer-PosorskeDivision of Hematology-Oncology, University of California San Diego, San Diego, CA 92037, USA.
Binav BaralDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-4141-3488
Daniel J MaDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-2957-4687
Scott C LesterDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
David M RoutmanDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Michelle A Neben-WittichDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Jessica M WilsonDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-0363-8002
Daniel L PriceDepartment of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Eric J MooreDepartment of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Kendall K TascheDepartment of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Katie M Van AbelDepartment of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Linda X YinDepartment of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Nathan R FosterDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.
Katharine PriceDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-5738-1866

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%;

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCisplatinDocetaxelFluorouracilOropharyngeal NeoplasmsPapillomavirus InfectionsPlatinumAdultAgedCarcinoma, Squamous CellChemoradiotherapyFemaleHuman Papillomavirus VirusesHumansInduction ChemotherapyMaleCisplatinDocetaxelFluorouracilPlatinumde-escalationHPVhuman papillomavirusinduction chemotherapyoropharyngeal canceroropharynx cancerplatinum doublet

Identifiers

PMID42043235
PMCPMC13120350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.